While NK cell researchers originally used IL-2, not the physiologically relevant IL-15 (since it was discovered later) to study NK cell biology, IL-2 is not globally viewed as an appropriate cytokine for targeting NK cells in cancer because of its preferential binding and activity on Tregs and activated T-cell subsets. The gene discussed is IL15; the disease is cancer.